The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure – a prospective, randomized, controlled prevention trial of the German Hypertension League
Authors:
- Stephan LüdersSLStephan Lüders
- Joachim SchraderJSJoachim Schrader
- Jürgen BergerJBJürgen Berger
- Thomas UngerTUThomas Unger
- Walter ZidekWZWalter Zidek
- Michael BöhmMBMichael Böhm
- Martin MiddekeMMMartin Middeke
- Wolfgang MotzWMWolfgang Motz
- Cornelia LübckeCLCornelia Lübcke
- Andrea GanszAGAndrea Gansz
- Ludmer BrokampLBLudmer Brokamp
- Roland E SchmiederRSRoland E Schmieder
- 1 July 2008
- journal article
- research article
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 26 (7) , 1487-1496
Abstract
The prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure study addresses the issue of whether progression to manifest hypertension in patients with high-normal blood pressure can be prevented with treatment. A total of 1008 participants with high-normal office blood pressure were randomized to ramipril treatment group (n = 505) and a control group (n = 503). The patients were followed up for 3 years. Primary endpoint was to prevent or delay the progression to manifest hypertension. Secondary endpoints were reduction in the incidence of cerebrovascular and cardiovascular events, as well as the development of hypertension as defined by ambulatory blood pressure monitoring. One hundred and fifty-five patients (30.7%) in the ramipril group, and 216 (42.9%) in the control group reached the primary endpoint (relative risk reduction 34.4%, P = 0.0001). Ramipril also proved to be more effective in reducing the incidence of manifest office hypertension in patients with baseline ambulatory blood pressure monitoring high-normal blood pressure. The incidence of cerebrovascular and cardiovascular events showed no statistically significant differences between the two groups. Cough was more frequent in the ramipril group (4.8 vs. 0.4%). There is now good clinical evidence that patients with high-normal blood pressure (prehypertension) are more likely to progress to manifest hypertension than patients with optimal or normal blood pressure. Additional ambulatory blood pressure monitoring seems to be essential to achieve correct diagnosis. Treatment of patients with high-normal office blood pressure with the angiotensin-converting enzyme inhibitor was well tolerated, and significantly reduced the risk of progression to manifest hypertension.Keywords
This publication has 16 references indexed in Scilit:
- Feasibility of Treating Prehypertension with an Angiotensin-Receptor BlockerNew England Journal of Medicine, 2006
- Twenty-four hour ambulatory blood pressure monitoringDMW - Deutsche Medizinische Wochenschrift, 2005
- White-Coat Hypertension as a Risk Factor for the Development of Home HypertensionArchives of internal medicine (1960), 2005
- Is Low-Risk Hypertension Fact or Fiction?Cardiovascular Risk Profile in the TROPHY StudyAmerican Journal of Hypertension, 2005
- 2003 European Society of Hypertension???European Society of Cardiology guidelines for the management of arterial hypertension*Journal Of Hypertension, 2003
- The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureThe JNC 7 ReportJAMA, 2003
- Masked HypertensionHypertension, 2002
- Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort studyThe Lancet, 2001
- Impact of High-Normal Blood Pressure on the Risk of Cardiovascular DiseaseNew England Journal of Medicine, 2001
- Isolated office hypertension: a prehypertensive state?Journal Of Hypertension, 1996